
Ayala Pharmaceuticals AYLA
Geschäftsbericht 2022
hinzugefügt 31.03.2023
Ayala Pharmaceuticals Zahlungsmittel 2011-2026 | AYLA
Zahlungsmittel Jährlich Ayala Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.41 M | 37 M | 42 M | 16.8 M | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 42 M | 2.41 M | 24.6 M |
Zahlungsmittel Vierteljährlich Ayala Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 11.2 M | 20.1 M | 27 M | 37 M | 41.2 M | 44.8 M | 56 M | 42 M | 42 M | 42 M | 42 M | 16.7 M | 16.7 M | 16.7 M | 16.7 M | 26.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 56 M | 11.2 M | 31.2 M |
Zahlungsmittel anderer Aktien in der Pharmaeinzelhändler
| Name | Zahlungsmittel | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M | ||
|
Acer Therapeutics
ACER
|
2.33 M | - | 2.71 % | $ 14 M | ||
|
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K | ||
|
AgeX Therapeutics
AGE
|
345 K | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | ||
|
AbCellera Biologics
ABCL
|
129 M | $ 3.55 | -2.18 % | $ 1.06 B | ||
|
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M | ||
|
ADMA Biologics
ADMA
|
87.6 M | $ 15.66 | -5.32 % | $ 3.73 B | ||
|
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M | ||
|
Aptorum Group Limited
APM
|
3.5 M | $ 0.82 | -0.73 % | $ 4.47 M | ||
|
Midatech Pharma plc
MTP
|
1.67 M | - | -18.52 % | $ 27.3 M | ||
|
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | ||
|
Alpine Immune Sciences
ALPN
|
13.4 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
118 M | - | 4.14 % | $ 49.1 M | ||
|
Apellis Pharmaceuticals
APLS
|
466 M | $ 20.16 | 1.51 % | $ 2.54 B | ||
|
Ampio Pharmaceuticals
AMPE
|
4.09 M | - | -11.43 % | $ 502 K | ||
|
ANI Pharmaceuticals
ANIP
|
145 M | $ 75.5 | -1.35 % | $ 1.46 B | ||
|
Applied Therapeutics
APLT
|
49.9 M | - | - | $ 8.42 M | ||
|
Autolus Therapeutics plc
AUTL
|
240 M | $ 1.48 | -9.2 % | $ 378 M | ||
|
Aravive
ARAV
|
53.7 M | - | -13.39 % | $ 1.45 M | ||
|
Adverum Biotechnologies
ADVM
|
60.7 M | - | - | $ 86.2 M | ||
|
Athersys
ATHX
|
37.4 M | - | 3.77 % | $ 22.4 M | ||
|
ARCA biopharma
ABIO
|
61.6 M | - | 1052.0 % | $ 415 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
120 M | $ 34.35 | -3.75 % | $ 3.57 B | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
13.7 M | $ 7.8 | -7.36 % | $ 33.8 M | ||
|
CorMedix
CRMD
|
43.6 M | $ 6.32 | -11.24 % | $ 322 M | ||
|
AVEO Pharmaceuticals
AVEO
|
70.5 M | - | - | $ 521 M | ||
|
Champions Oncology
CSBR
|
9.78 M | $ 5.79 | -3.58 % | $ 79.1 M | ||
|
Axsome Therapeutics
AXSM
|
323 M | $ 160.44 | -2.22 % | $ 7.98 B | ||
|
BridgeBio Pharma
BBIO
|
570 M | $ 65.38 | -1.74 % | $ 12.5 B | ||
|
Denali Therapeutics
DNLI
|
175 M | $ 19.69 | -3.34 % | $ 3.24 B | ||
|
Brainstorm Cell Therapeutics
BCLI
|
187 K | - | -2.5 % | $ 5.88 M | ||
|
BioDelivery Sciences International
BDSI
|
112 M | - | -4.8 % | $ 255 M | ||
|
Acasti Pharma
ACST
|
22.1 M | - | 4.01 % | $ 150 M | ||
|
BeiGene, Ltd.
BGNE
|
4.55 B | - | 0.49 % | $ 251 B | ||
|
Edesa Biotech
EDSA
|
1 M | $ 3.8 | -10.9 % | $ 12.2 M | ||
|
Equillium
EQ
|
23.2 M | $ 1.79 | 2.0 % | $ 62.2 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
21.8 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
86.5 M | - | -7.31 % | $ 87 M | ||
|
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | ||
|
Aeterna Zentaris
AEZS
|
16.4 M | - | 5.93 % | $ 314 M | ||
|
Bellerophon Therapeutics
BLPH
|
6.92 M | - | -74.18 % | $ 955 K | ||
|
BioLineRx Ltd.
BLRX
|
10.4 M | $ 2.75 | -2.14 % | $ 908 M | ||
|
BioMarin Pharmaceutical
BMRN
|
1.31 B | $ 60.47 | 0.07 % | $ 11.6 B | ||
|
Eton Pharmaceuticals
ETON
|
21.4 M | $ 17.04 | -2.77 % | $ 437 M |